- Conditions
- Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
- Interventions
- Cyanocobalamin, Dulaglutide
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes
- Interventions
- Dulaglutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 20 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Orforglipron, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 17
- States / cities
- Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
- Conditions
- Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 44,671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, LY2189265, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 884 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 36
- States / cities
- Concord, California • La Mesa, California • Lancaster, California + 33 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dulaglutide, Placebo, Insulin Glargine, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 13
- States / cities
- Fresno, California • San Mateo, California • Tustin, California + 10 more
- Conditions
- Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
- Interventions
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Procedure · Drug
- Lead sponsor
- Ali Aminian
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
- Interventions
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Drug · Diagnostic Test
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- LY2189265
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Diabetes Mellitus, Type 1, Endothelial Dysfunction
- Interventions
- Dulaglutide, Placebo
- Drug
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Dulaglutide, Semaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 70,000 participants
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Concord, California • Covina, California + 106 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dulaglutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 38
- States / cities
- Glendale, California • Greenbrae, California • Huntington Park, California + 35 more
- Conditions
- Healthy
- Interventions
- Dulaglutide (Reference), Dulaglutide (Test)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- LY2189265, Liraglutide, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Chino, California • Fresno, California + 15 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Metformin, LY2189265, Placebo (oral), Placebo (subcutaneous)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 807 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Buena Park, California + 25 more
- Conditions
- Obesity & Overweight, Diabetes (DM)
- Interventions
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2039
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Type 2 Diabetes, Overweight, ASCVD
- Interventions
- Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60,000 participants
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
- Interventions
- Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,842 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 72
- States / cities
- Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 67 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2189265 and Lifestyle Measures, Placebo solution and Lifestyle Measures
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 12
- States / cities
- Concord, California • Lancaster, California • Mission Hills, California + 9 more
- Conditions
- Type 2 Diabetes
- Interventions
- LY3502970, Dulaglutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 20
- States / cities
- Anaheim, California • Huntington Park, California • Los Angeles, California + 17 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- semaglutide, Dulaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 100
- States / cities
- Tuscumbia, Alabama • Chandler, Arizona • Phoenix, Arizona + 85 more